This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity and (b) an antibody or an antigen-binding portion thereof that specifically binds to a Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity.本發明提供用於治療罹患肺癌之個體的方法,該方法包含投予該個體治療有效量之:(a)特異性結合程序性死亡-1(PD-1)受體並抑制PD-1活性之抗體或其抗原結合部分;及(b)特異性結合細胞毒性T淋巴球抗原-4(CTLA-4)並抑制CTLA-4活性之抗體或其抗原結合部分。
